Floatz logo

40 assets in Rectum Adenocarcinoma

Therapeutic assets addressing Rectum Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Rectum Adenocarcinoma
Merck Sharp & Dohme LLCP3BBB (75)
Irinotecan
Rectum Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen UniversityP3BBB (74)
Cetuximab
Rectum Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen UniversityP3BB (68)
Oxaliplatin
Rectum Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen UniversityP3BB (68)
Regorafenib
Rectum Adenocarcinoma
City of Hope Medical CenterP2BB (64)
Tipiracil
Rectum Adenocarcinoma
Sir Run Run Shaw HospitalP2BB (64)
Trifluridine
Rectum Adenocarcinoma
Sir Run Run Shaw HospitalP2BB (64)
Capecitabine
Rectum Adenocarcinoma
Chongqing University Cancer HospitalP3B (63)
Nivolumab
Rectum Adenocarcinoma
National Cancer Institute (NCI)P2B (63)
Vandazole
Rectum Adenocarcinoma
AC Camargo Cancer CenterP4B (63)
Encorafenib
Rectum Adenocarcinoma
National Cancer Institute (NCI)P2B (61)
Balstilimab
Rectum Adenocarcinoma
City of Hope Medical CenterP2B (60)
Botensilimab
Rectum Adenocarcinoma
City of Hope Medical CenterP2B (60)
Ipilimumab
Rectum Adenocarcinoma
National Cancer Institute (NCI)P2B (59)
Pucotenlimab
Rectum Adenocarcinoma
Sun Yat-sen UniversityP3B (59)
Trastuzumab
Rectum Adenocarcinoma
Academic and Community Cancer Research UnitedP2B (57)
Atezolizumab
Rectum Adenocarcinoma
Georgetown UniversityP3CCC (54)
Calderasib
Rectum Adenocarcinoma
Merck Sharp & Dohme LLCP3CCC (54)
Levofolinic Acid
Rectum Adenocarcinoma
Merck Sharp & Dohme LLCP3CCC (54)
Ipalolimab
Rectum Adenocarcinoma
Sir Run Run Shaw HospitalP2CCC (53)
Probio-M9
Rectum Adenocarcinoma
Seventh Medical Center of PLA General HospitalP2CCC (53)
Tovorilimab
Rectum Adenocarcinoma
Sir Run Run Shaw HospitalP2CCC (53)
Tucatinib
Rectum Adenocarcinoma
Academic and Community Cancer Research UnitedP2CCC (53)
Adebrelimab
Rectum Adenocarcinoma
Sir Run Run Shaw HospitalP2CCC (51)
Cabozantinib
Rectum Adenocarcinoma
University of Colorado, DenverP2CCC (51)
Dostarlimab
Rectum Adenocarcinoma
Memorial Sloan Kettering Cancer CenterP2CCC (51)
Galunisertib
Rectum Adenocarcinoma
Providence Health & ServicesP2CCC (51)
Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101)
Rectum Adenocarcinoma
Chongqing University Cancer HospitalP2CCC (51)
Ivonescimab
Rectum Adenocarcinoma
Sun Yat-sen UniversityP2CCC (51)
Serplulimab
Rectum Adenocarcinoma
Chongqing University Cancer HospitalP2CCC (51)
Toripalimab
Rectum Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen UniversityP2CCC (51)
Trastuzumab Deruxtecan
Rectum Adenocarcinoma
Gruppo Oncologico del Nord-OvestP2CCC (51)
Abemaciclib
Rectum Adenocarcinoma
M.D. Anderson Cancer CenterP1/2CCC (48)
SX682
Rectum Adenocarcinoma
M.D. Anderson Cancer CenterP1/2CCC (48)
Temuterkib
Rectum Adenocarcinoma
M.D. Anderson Cancer CenterP1/2CCC (48)
Polypepi1018
Rectum Adenocarcinoma
Mayo ClinicP1CC (47)
Papaverine
Rectum Adenocarcinoma
City of Hope Medical CenterP1CC (43)
Rifaximin
Rectum Adenocarcinoma
Mansoura UniversityP1/2CC (43)
Atx-559
Rectum Adenocarcinoma
Accent TherapeuticsP1C (39)
Ropidoxuridine
Rectum Adenocarcinoma
National Cancer Institute (NCI)P1C (38)